Association of HLA-DRB1 with Recurrent Aphthous Stomatitis in Northeast Iranian Population | ||
Reviews in Clinical Medicine | ||
مقاله 4، دوره 7، شماره 3، آذر 2020، صفحه 114-118 اصل مقاله (446.62 K) | ||
نوع مقاله: Original article | ||
شناسه دیجیتال (DOI): 10.22038/rcm.2020.50604.1330 | ||
نویسندگان | ||
Nooshin Mohtasham1؛ Hooshang Rafatpanah2؛ Atessa Pakfetrat3؛ Reza Zare1؛ Hamideh Kade4؛ Mahshad Hosseini shad3؛ Maryam Zamanzadeh5؛ Farnaz Mohajertehran* 6 | ||
1Oral and Maxillofacial Disease Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. | ||
2Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
3Department of Oral and Maxillofacial Diseases, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran. | ||
4Oral & Dental Disease Research Center, Department of Oral & Maxillofacial Pathology, School of Dentistry, Zahedan University of Medical Science, Zahedan, Iran. | ||
5Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran. | ||
6Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. | ||
چکیده | ||
Introduction:Recurrent aphthous ulcers are the most common pathologic conditions of the oral cavity, which despite having clear clinical features, the etiology is unknown. This study aimed to determine the relationship between one of the histocompatibility antigens (HLA DRB1) and its sub-groups with the incidence of recurrent aphthous ulcers in an Iranian population (North East of Iran). Methods: In this case-control study, a total of 72 patients with recurrent aphthous ulcers and 70 healthy subjects in Northeast Iranian population were included. Genotyping was done by polymerase chain reaction-specific sequence primers (PCR- SSP) for each sample, according to standard kit protocol (BAG- Germany). Results: In 72 patients with recurrent aphthous ulcers that were included in this study, 26 were male and 46 were female; of the 70 control patients, this difference not significant statistically (P>0.05). The frequency of HLA -DRB1 *16 was 0.7% in the healthy subjects, however frequency of HLA -DRB1 *16 in patients with recurrent aphthous stomatitis (RAS) was 42.36%, and this difference was statistically significant (P=0.03). But, this difference was not observed in other subgroups. Conclusion: The frequency of DRB1 * 16 in the patients with RAS were higher than the group. Therefore, DRB1 * 16 can be suggested as a Predisposing factor for aphthous ulcers patients. | ||
کلیدواژهها | ||
Antigens؛ Aphthous.HLA-DRB1 Chains؛ PCR | ||
اصل مقاله | ||
Introduction predisposition, infectious disease, allergic reaction to food, deficiency of vitamins, digestive problems, mechanical damage, and stress (3, 11). Methods Genomic DNA Extraction and PCR-SSP Technique
Figure 1. Gel electrophoresis of HLA-DRB1* PCR-SSP from recurrent aphthous stomatitis patients DNA. Internal control Bands are in all samples. Statistical Analysis Result
Conclusion Acknowledgement Conflicts of interest
| ||
مراجع | ||
1. Simeone, J.C., et al., An evaluation of variation in published estimates of schizophrenia prevalence from 1990─ 2013: a systematic literature review. BMC psychiatry, 2015. 15(1): p. 193. 2. Wu, Y., et al., Epidemiology of schizophrenia and risk factors of schizophrenia-associated aggression from 2011 to 2015. Journal of International Medical Research, 2018. 46(10): p. 4039-4049. 3. Guessoum, S.B., et al., A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020: p. 109862. 4. Mitra, S., et al., Antioxidant and anti-inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017. 78: p. 1-11. 5. Wang, H., et al., cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia. Frontiers in molecular neuroscience, 2018. 11: p. 255. 6. Rabinowitz, J., et al., Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res, 2012. 137(1-3): p. 147-50. 7. Cicero, D.C., et al., Common taxonomy of traits and symptoms: linking schizophrenia symptoms, schizotypy, and normal personality. Schizophrenia bulletin, 2019. 45(6): p. 1336-1348. 8. Rossell, S.L., et al., N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. BMC Psychiatry, 2016. 16(1): p. 320. 9. Hope, J. and N. Keks, Chronic schizophrenia and the role of the general practitioner. Australian Family Physician, 2015. 44(11): p. 802. 10. Yao, J.K. and M.S. Keshavan, Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal, 2011. 15(7): p. 2011-35. 11. McCutcheon, R.A., A. Abi-Dargham, and O.D. Howes, Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends in neurosciences, 2019. 42(3): p. 205-220. 12. Kumar, J., et al., Glutathione and glutamate in schizophrenia: a 7T MRS study. Molecular psychiatry, 2018: p. 1-10. 13. Bryll, A., et al., Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia. Biomolecules, 2020. 10(3): p. 384. 14. Reddy, R. and R. Reddy, Antioxidant therapeutics for schizophrenia. Antioxidants & redox signaling, 2011. 15(7): p. 2047-2055. 15. Arakawa, M. and Y. Ito, N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum, 2007. 6(4): p. 308-14. 16. Choy, K.H., et al., Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. Eur J Pharmacol, 2010. 649(1-3): p. 224-8. 17. Holmay, M.J., et al., N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol, 2013. 36(4): p. 103-6. 18. McQueen, G., et al., Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. Psychopharmacology, 2020. 237(2): p. 443-451. 19. Steullet, P., et al., Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience, 2006. 137(3): p. 807-19. 20. Gere-Paszti, E. and J. Jakus, The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr, 2009. 23(6): p. 658-64. 21. Otte, D.-M., et al., N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology, 2011. 36(11): p. 2233-2243. 22. Csontos, C., et al., Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn. Burns, 2012. 38(3): p. 428-437. 23. Kigerl, K.A., et al., System xc− regulates microglia and macrophage glutamate excitotoxicity in vivo. Experimental neurology, 2012. 233(1): p. 333-341. 24. Frye, R.E., The Physiological Effects of N-Acetylcysteine in Clinical Studies, in The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. 2019, Springer. p. 331-348. 25. Bulut, M., et al., Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry, 2009. 10(4 Pt 2): p. 626-8. 26. Berk, M., et al., Qualitative methods in early-phase drug trials: Broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. The Journal of clinical psychiatry, 2011. 27. Shetty, R., et al., Mechanisms and Therapeutics of N-acetylcysteine: A Recent Update. Research Journal of Pharmacy and Technology, 2019. 12(5): p. 2584-2588. 28. Carmeli, C., et al., Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PloS one, 2012. 7(2). 29. Berk, M., et al., N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry, 2008. 64(5): p. 361-8. 30. Berk, M., et al., N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biological psychiatry, 2008. 64(6): p. 468-475. 31. Gadallah, A.-H.A., et al., Efficacy and Safety of N-Acetyl-Cysteine as Add-on Therapy in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis. Journal of Obsessive-Compulsive and Related Disorders, 2020: p. 100529. 32. Rapado-Castro, M., et al., Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med, 2017. 47(5): p. 866-876. 33. Rapado-Castro, M., et al., Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychological medicine, 2017. 47(5): p. 866-876. 34. Willborn, R.J., C.P. Hall, and M.A. Fuller, Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia. Mental Health Clinician, 2019. 9(3): p. 116-123. 35. Sansone, R.A. and L.A. Sansone, Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci, 2011. 8(1): p. 10-4. 36. Tsai, G.E. and P.Y. Lin, Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des, 2010. 16(5): p. 522-37. 37. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 2009. 151(4): p. 264-9, w64. 38. Association, A.P., Diagnostic and statistical manual of mental disorders (DSM-5®). 2013: American Psychiatric Pub. 39. Kay, S.R., A. Fiszbein, and L.A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987. 13(2): p. 261-76. 40. Jadad, A.R., et al., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996. 17(1): p. 1-12. 41. Gopalakrishnan, S. and P. Ganeshkumar, Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare. J Family Med Prim Care, 2013. 2(1): p. 9-14. 42. Rapado-Castro, M., et al., Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2015. 57: p. 69-75. 43. Higgins, J.P., et al., The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj, 2011. 343: p. d5928. 44. Breier, A., et al., Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res, 2018. 45. Farokhnia, M., et al., N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol, 2013. 36(6): p. 185-92. 46. Sepehrmanesh, Z., et al., Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry, 2018. 82: p. 289-296. 47. Anzures-Cabrera, J. and J.P. Higgins, Graphical displays for meta-analysis: An overview with suggestions for practice. Res Synth Methods, 2010. 1(1): p. 66-80. 48. Haddad, P.M. and C.U. Correll, The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Therapeutic advances in psychopharmacology, 2018. 8(11): p. 303-318. 49. Magalhães, P.V., et al., Antioxidant treatments for schizophrenia. Cochrane Database of Systematic Reviews, 2016(2). 50. Atkuri, K.R., et al., N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Current opinion in pharmacology, 2007. 7(4): p. 355-359. 51. McEvoy, J.P., et al., Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 2006. 163(4): p. 600-10. 52. Dean, O., F. Giorlando, and M. Berk, N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Journal of psychiatry & neuroscience: JPN, 2011. 36(2): p. 78. 53. Chakraborty, S., et al., N-acetyl cysteine ameliorates depression-induced cognitive deficits by restoring the volumes of hippocampal subfields and associated neurochemical changes. Neurochemistry international, 2020. 132: p. 104605. 54. Howes, O., R. McCutcheon, and J. Stone, Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol, 2015. 29(2): p. 97-115. 55. Farokhnia, M., et al., A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology (Berl), 2014. 231(3): p. 533-42. 56. Shi, H., et al., Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2020. 20: p. 1-9. 57. Garcia, R.J., et al., Brief report: attention deficit and hyperactivity disorder scores are elevated and respond to n‐acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis & Rheumatism, 2013. 65(5): p. 1313-1318. 58. Edwards, M., et al., N-acetylcysteine and Unverricht–Lundborg disease Variable response and possible side effects. Neurology, 2002. 59(9): p. 1447-1449. 59. Nüesch, E., et al., Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. Bmj, 2010. 341: p. c3515. 60. Chue, P. and J.K. Lalonde, Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric disease and treatment, 2014. 10: p. 777. | ||
آمار تعداد مشاهده مقاله: 492 تعداد دریافت فایل اصل مقاله: 269 |